Article Sidebar

PDF
Date Published: 15/02/2023
Abstract Views: 136
Views PDF: 76
DOI: https://doi.org/10.51298/vmj.v521i2.4097
Issue
Vol. 521 No. 2 (2022)
Section
Các bài báo
How to Cite
Vũ , V. T., & Phạm , C. P. (2023). FIRST-LINE OUTCOME TREATMENT THE FIRST-GENERATION TYROSINE KINASE INHIBITORS IN FEMALE PATIENTS WITH STAGE IIIB-IV NON-SMALL CELL LUNG CANCER. Vietnam Medical Journal, 521(2). https://doi.org/10.51298/vmj.v521i2.4097

FIRST-LINE OUTCOME TREATMENT THE FIRST-GENERATION TYROSINE KINASE INHIBITORS IN FEMALE PATIENTS WITH STAGE IIIB-IV NON-SMALL CELL LUNG CANCER

Văn Thịnh Vũ 1,, Cẩm Phương Phạm 2
1 Vietnam-Sweden hospital
2 Bach Mai hospital

Main Article Content

Abstract

Objectives: To evaluate the results of the first-line therapy after the first-generation tyrosine kinase receptor inhibitors (TKIs) in female patients with non-small cell lung cancer (NSCLC) stage IIIB-IV. Subjects and methods: Regression study on 75 female patients with NSCLC stage IIIB-IV, harboring EGFR mutation, received 1st generation TKIs as first-line treatment at Bach Mai hospital from 2019-2021. Results: Partial response rate 76%, no patient had complete response. Disease control rate is 93,3%. Response to brain damage 59,1%. The response was higher in the group having the adverse event in the skin with both gefitinib and erlotinib (statistically significant). Prolonged progression-free survival was 12,5±0,6 months, median of 12 months. The prolonged progression-free survival median of two groups using gefitinib and erlotinib as first-line treatment is non statistical significance. The independent factors that have a good influence on prolonged progression-free survival are the whole state just before treatment: the ECOG PS value 0-1, the exon 19 mutation and adverse events in the skin (rash). Common adverse events were rash and diarrhea, the majority I and II. The rates of treatment discontinuation and dose reduction due to low toxicity were 2,7% and 1,3%.

Article Details

Keywords

Non-small cell lung cancer, female, EGFR mutation, Gefitinib, Erlotinib

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
2. Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.
3. Đỗ Mai Linh, Lê Văn Quảng, Nguyễn Tuyết Mai. Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ bằng thuốc ức chế Tyrosine Kinase, Tạp chí ung thư học Việt Nam. 2017; 3: 86-93.
4. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS). JCO. 2011;29(21):2866-2874.
5. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology. 2011;12(8):735-742.
6. Kashima J, Okuma Y, Miwa M et al (2016), Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors, Med Oncol. 33(11), 129.
7. Petrelli F., Borgonovo K., Cabiddu M. et al (2012). Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer Amst Neth, 78(1), 8-15.
8. Urata Y, Katakami N, Morita S et al. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L, J Clin Oncol. 2016; 24(27): 3248-57.